Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03012100 | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | active not recruiting | Phase 2 | 280 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06449222 | Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy | active not recruiting | Phase 2 | 83 | BioNTech SEINDUSTRY | 4 | Jun 30, 2026 |
| clinicaltrials |
| NCT03032406 | CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer | active not recruiting | Phase 2 | 53 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06008158 | Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca | active not recruiting | Phase 2 | 48 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT01273610 | Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer | active not recruiting | Phase 2 | 40 | City of Hope Medical CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT02750358 | Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer | active not recruiting | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT02764541 | Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) | active not recruiting | Phase 2 | 195 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05323955 | Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib(BRIDGET) | active not recruiting | Phase 2 | 48 | Carey Anders, M.D.OTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04298086 | A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer | active not recruiting | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04837209 | Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer(NADiR) | active not recruiting | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT00929214 | Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients | active not recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05226663 | A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05563220 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer(ELEVATE) | active not recruiting | Phase 1 / Phase 2 | 435 | Stemline Therapeutics, Inc.INDUSTRY | 13 | Jun 12, 2026 | clinicaltrials |
| NCT02971748 | Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03202316 | Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer | active not recruiting | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05558722 | Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer(ACNTBC) | active not recruiting | Phase 2 | 31 | Xijing HospitalOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02644369 | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors(INSPIRE) | active not recruiting | Phase 2 | 100 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT02738866 | Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor | active not recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT00609791 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer | active not recruiting | Phase 2 | 40 | City of Hope Medical CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03768492 | Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy(ReDCoAT) | active not recruiting | Phase 2 | 60 | NYU Langone HealthOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT02927912 | Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction | active not recruiting | Phase 2 | 108 | Ohio State University Comprehensive Cancer CenterOTHER | 2 | Jun 3, 2026 | clinicaltrials |
| NCT05203445 | A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer | active not recruiting | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04568616 | Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)(NAOMI) | active not recruiting | Phase 2 | 178 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT04588545 | Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease | active not recruiting | Phase 1 / Phase 2 | 33 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT00585507 | Efficacy and Safety of 500mg of Fulvestrant | active not recruiting | Phase 2 | 40 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT00877500 | Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | active not recruiting | Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03125928 | Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | active not recruiting | Phase 2 | 16 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05392608 | SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)(SEQUEL-Breast) | active not recruiting | Phase 2 | 130 | Borstkanker Onderzoek GroepNETWORK | 1 | May 22, 2026 | clinicaltrials |
| NCT05675579 | A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) | active not recruiting | Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03587740 | ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer | active not recruiting | Phase 2 | 111 | Dana-Farber Cancer InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06618014 | Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)(NeoTOP) | active not recruiting | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05296746 | Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer(RIBOLARIS) | active not recruiting | Phase 2 | 1,100 | SOLTI Breast Cancer Research GroupOTHER | 3 | May 14, 2026 | clinicaltrials |
| NCT05812924 | A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause | active not recruiting | Phase 2 | 18 | University of MiamiOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03609047 | Adjuvant Palbociclib in Elderly Patients With Breast Cancer(Appalaches) | active not recruiting | Phase 2 | 366 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | May 12, 2026 | clinicaltrials |
| NCT03941730 | Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer | active not recruiting | Phase 2 | 8 | Mayo ClinicOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT01621659 | Multidisciplinary Team IntervenTion in CArdio-ONcology (TITAN Study)(TITAN) | active not recruiting | Phase 2 | 80 | University of AlbertaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05319873 | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05498896 | Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC(BARBICAN) | active not recruiting | Phase 2 | 146 | Queen Mary University of LondonOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06048718 | T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases(TUXEDO-4) | active not recruiting | Phase 2 | 28 | MedSIROTHER | 2 | May 8, 2026 | clinicaltrials |
| NCT05596409 | ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study(ELCIN) | active not recruiting | Phase 2 | 61 | Stemline Therapeutics, Inc.INDUSTRY | 6 | May 7, 2026 | clinicaltrials |
| NCT04553133 | PF-07104091 as a Single Agent and in Combination Therapy | active not recruiting | Phase 2 | 157 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT04647916 | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases | active not recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT05591547 | Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen(APBI RISE) | active not recruiting | Phase 2 | 91 | Sanford HealthOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06125522 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | active not recruiting | Phase 1 / Phase 2 | 11 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT01245712 | Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer | active not recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04733118 | Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer(PHERGAIN-2) | active not recruiting | Phase 2 | 393 | MedSIROTHER | 5 | Apr 29, 2026 | clinicaltrials |
| NCT06172127 | PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer(DEMETHER) | active not recruiting | Phase 2 | 165 | MedSIROTHER | 5 | Apr 29, 2026 | clinicaltrials |
| NCT03789110 | NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 30, 2026source: clinicaltrials